Faron Pharmaceuticals Ltd (LON:FARN)

Faron Pharmaceuticals Ltd (LON:FARN)

Share Price
146.00 p
-6 (-3.95 %)
Market Cap
£54.36 m
Proactive Investors - Run By Investors For Investors

Faron Pharmaceuticals Ltd

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.

Market: AIM:FARN
52-week High/Low: 168.000p / 50.050p
Sector: Pharma & Biotech
Market Cap: £54.36 m
Website: www.faron.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Faron Pharmaceuticals Ltd

Faron Pharmaceuticals Ltd Snapshot

Our values

Faron is all about science. We are all about people.  It's all about saving lives.
Our values outline the Faron story and summarize our identity. These two cornerstones of our existence are deeply intertwined. High-quality science makes medical discovery and innovation possible. Dedicated people make high-quality science and product development possible.

Our values tell everyone what we are all about. In the end, it’s all about saving lives.

Through exciting, new and challenging science we want to discover ground-breaking ways to battle diseases that are difficult to cure. All our determined, passionate and trustworthy professionals want to make life better for people suffering from devastating diseases.

"Research and development to find treatments for severe diseases with serious unmet medical needs is what we do. I am proud and excited to be among this group of people working hard, facing challenges and understanding the humane purpose of science. ” Dr Markku Jalkanen, CEO



Therapeutic areas

”Endothelial barrier is everything” - The endothelial surface of exhaustive capillary networks of central organs controls the fluid and cell balance between circulation and tissues. The endothelium is also a critical factor in many devastating diseases, such as organ failure and cancer metastasis. Faron’s pipeline is based on endothelial receptors involved in the regulation of immune responses and cell signalling.

Faron develops novel treatments for life-threatening medical conditions with significant unmet needs. Faron's core therapeutic areas are Acute Respiratory Syndrome (ARDS), organ protection and modulation of the immune system.


Traumakine (FP-1201-lyo)

Traumakine® (FP-1201-lyo), is based on a patent-protected use of intra-venous interferon beta to prevent capillary leakage in organs under threat of ischemia and inflammation. The active pharmaceutical ingredient in Traumakine® is recombinant human IFN beta-1a. The lead indication for Traumakine® is Acute Respiratory Distress Syndrome (ARDS).

ARDS Mode of Disease
The fundamental role of endothelial barrier in ARDS. Read more on ARDS (link to Patients & Physician: “Information on ARDS”)

The mechanism behind Traumakine® development was invented by scientists at Turku University from 1995 to 2003. Through extensive research and ex-vivo studies, it was identified that a molecule called CD73 is an essential entity needed to maintain endothelial barrier function. CD73 is an ectoenzyme capable of breaking down extracellular AMP to produce locally active adenosine (Figure 1). Adenosine maintains the endothelial barrier and downregulates inflammation escalation, preventing both early vascular leakage and escalation of inflammation, which are the two early patho-physiological events leading to Acute Respiratory Distress Syndrome (ARDS).

One of the key findings that led to the development of Traumakine®, was a discovery that interferon beta-1a could enhance CD73 expression and therefore could be used to treat a range of vascular leakage conditions including ARDS. Traumakine® works by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine such that vascular leaking and escalation of inflammation are reduced.

Traumakine mechanism of action

Figure 1: The anti-inflammatory role CD73 in endothelium

The sub-cutaneous and intra-muscular use of recombinant human IFN beta-1a is an approved treatment for patients with relapsing remitting MS and the safety profile of recombinant human IFN beta-1a in such patients is well characterized.

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Promising Innovative Medicines (PIM) designation for Traumakine®. The award of PIM designation is the first stage of the MHRA's Early Access Medicines Scheme (EAMS) and is granted when a medicine shows early signals, based on evidence to date, that it may be a possible candidate for the scheme. PIM designation under the EAMS also illustrates that a medicine has potential value in a disease area with significant and urgent unmet need and further qualifies an accompanying application and progression of the medicine towards the next stage in the EAMS process, which also allows early pricing negotiation with the UK National Institute for Health and Care Excellence (NICE). Find out the Traumakine® mechanism of action, presented by Professor Geoff Bellingan, medical director at University College London Hospitals (UCLH), who led the Phase II trial.

Traumakine® is currently under clinical investigations in ARDS and for prevention of multi-organ failure (MOF) after emergency aortic surgery. The Company recently announced that the INTEREST trial did not meet its primary end point, however the treatment benefit was seen in subgroups of patients identified with biomarkers. The Company is currently investigating the root cause.


Clevegen (FP-1305)

One of Faron’s key areas of focus is to develop a cancer treatment which supports the patients’ own immune defences against tumours, as these are often suppressed in cancer patients. This program is called Clevegen and it revolves around a key immunological switch expressed under immunosuppressive conditions named CLEVER-1, Common Lymphatic Endothelial and Vascular Endothelial Receptor 1, which in pre-clinical studies is proven to be involved in cancer growth and spread.

The active pharmaceutical ingredient of Clevegen® is a humanized anti-Clever-1 antibody. Clevegen can switch immune suppression to immune activation in various conditions: immune-oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called 'Turn-it' ("Turn on your immunity") may be used alone or in combination with other cancer treatments.

Read more about the therapeutic areas and technologies we are exploring with Clevegen.

All tumours are infiltrated by immune cells, for example macrophages, neutrophils, T-cells, dendritic cells, mast cells, myeloid derived suppressor cells and natural killer cells. Depending on the immune cells stimulated and activated, they can either have a protective effect for the host through suppression of tumour growth or deleterious effect by promoting tumour growth, invasion, metastasis and angiogenesis. Tumour associated macrophages (TAMs) have emerged as an essential constituent of the tumour micro-environment, with influence over many aspects of cancer (proliferation and survival) as well as interaction with surrounding elements (angiogenesis, escape from antitumour specific immunity). When TAMs populate a tumour, one of the very significant influences they exert over it, is a strong increase in immune suppression. Clever-1-positive TAMs represent one major macrophage population involved in this elimination of host immune system activity against the tumour cells. Clevegen® is an anti-Clever-1 antibody which targets and eliminates Clever-1-positive TAM’s from cancer patients.

Turning on your immunity
Clevegen is an anti-Clever-1 antibody which targets Clever-1-positive TAMs in cancer patients and converts these highly immunosuppressive type 2 “healing” macrophages (M2) to type 1 “pro-inflammatory” macrophages (M1) (Figure below). M1 macrophages secrete TNF alpha and interferon gamma and home cytotoxic T cells into the tumour, which are key in killing cancer cells.

Clevegen also prevents TAM infiltration into a tumour and therefore blocks TAM accumulation at tumour sites and can, therefore, also control the tumour content of regulatory T-cells, which are dependent on TAMs in the tumour microenvironment. The reduction of activated regulatory T-cells within the tumour makes the tumour more susceptible to treatment and the host’s




Board of Directors

Image of "Dr Frank Armstrong"
Dr Frank Armstrong
Non-Executive Chairman
Image of "Matti Manner"
Matti Manner
LL.M. - Non-Executive Vice-Chairman
Image of "Dr Markku Jalkanen"
Dr Markku Jalkanen
PhD - Chief Executive Officer
Image of "Yrjö E K Wichmann"
Yrjö E K Wichmann
M.Sc (econ.) - Chief Financial Officer
Image of "Leopoldo Zambeletti"
Leopoldo Zambeletti
Non-Executive Director
John Poulos
John Poulos
Non-Executive Director
Dr Gregory B. Brown
Non-Executive Director


Faron Pharmaceuticals
Joukahaisenkatu 6, Intelligate
FI-20520 TURKU

For visiting us, please use the lift of the Intelligate I building and press the button to the 6th Floor.

Phone: +358 2 469 5151
Fax: +358 2 469 5152
Email: [email protected]

Faron is located next to the Kupittaa railway station (Turku–Helsinki connection) and by the Helsinki motorway (E18). Driving from Helsinki, you should take the Kupittaa exit.


Please see below for details of the Company's Nominated Adviser and other key advisers.

Nominated Adviser and Broker

Panmure Gordon (UK) Limited
One New Change
London EC4M 9AF

Equity Adviser

RX Securities
Third Floor
1 Fore Street
London EC2Y 9DT

Solicitors to the Company as to English law

Jones Day
21 Tudor Street
London EC4Y 0DY

Solicitors to the Company as to Finnish law

Hannes Snellman Attorneys Ltd
Eteläesplanadi 20
PO Box 333
00130/00131 Helsinki

Auditors to the Company

Pricewaterhouse Coopers Oy
P.O. Box 1015
Itämerentori 2
FI-00101 Helsinki

Public Relations

Consilium Strategic Communications
41 Lothbury

Westwicke Partners, IR (US)
2800 Quarry Lake Drive
Baltimore, MD 21209


Investor Services Plc
The Pavilions
Bridgwater Road
Bristol BS13 8AE

Finnish Registrar

Euroclear Finland Ltd
Urho Kekkosen katu 5C
Pl 1110, 00101 Helsinki


Faron Pharmaceuticals
Joukahaisenkatu 6, Intelligate
FI-20520 TURKU

For visiting us, please use the lift of the Intelligate I building and press the button to the 6th Floor.

Phone: +358 2 469 5151
Fax: +358 2 469 5152
Email: [email protected]

Faron is located next to the Kupittaa railway station (Turku–Helsinki connection) and by the Helsinki motorway (E18). Driving from Helsinki, you should take the Kupittaa exit.

Columns Including FARN


Market Reports Including FARN

Video RSS



© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use